Dilaudid and Infusion site mass - a phase IV clinical study of FDA data

Summary:

Infusion site mass is reported as a side effect among people who take Dilaudid (hydromorphone hydrochloride), especially for people who are female, 40-49 old, also take Norco, and have Post laminectomy syndrome.

The phase IV clinical study analyzes which people have Infusion site mass when taking Dilaudid. It is created by eHealthMe based on reports of 95,518 people who have side effects when taking Dilaudid from the FDA, and is updated regularly.

What is Dilaudid?

Dilaudid has active ingredients of hydromorphone hydrochloride. It is often used in pain. eHealthMe is studying from 96,466 Dilaudid users. Check the latest studies of Dilaudid.

What is Infusion site mass?

Infusion site mass is found to be associated with 234 drugs and 127 conditions by eHealthMe. Check the latest studies of Infusion site mass.

On Jul, 19, 2026

95,518 people reported to have side effects when taking Dilaudid.
Among them, 48 people (0.05%) have Infusion site mass.

Could Dilaudid cause Infusion site mass?

Among these 48 people:

What is the gender of people who have Infusion site mass when taking Dilaudid? *

female: 81.25 %
male: 18.75 %

What is the age of people who have Infusion site mass when taking Dilaudid? *

What are other drugs people take besides Dilaudid? *

What are other side effects people have besides Infusion site mass? *

Hypoaesthesia (reduced sense of touch or sensation): 15 people, 31.25%
Nausea (feeling of having an urge to vomit): 13 people, 27.08%
Memory Loss: 10 people, 20.83%
Drug Withdrawal Syndrome (interfere with normal social, occupational, or other functioning. are not due to another medical condition, drug use, or discontinuation): 10 people, 20.83%
Therapeutic Response Decreased (less preventive response): 10 people, 20.83%
Fall: 10 people, 20.83%
Pain In Extremity: 9 people, 18.75%
Overdose: 8 people, 16.67%
Medical Device Discomfort (difficulty due to medical devices): 7 people, 14.58%
Diarrhea: 7 people, 14.58%

What are the existing conditions these people have? *

Post Laminectomy Syndrome: 8 people, 16.67%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 6 people, 12.50%
Immunodeficiency Common Variable: 3 people, 6.25%
Spinal Pain (pain in spine): 2 people, 4.17%
Immune System Disorder: 2 people, 4.17%
Neuromuscular Blockade: 1 person, 2.08%

* Approximation only. Some reports may have incomplete information.

Do you take Dilaudid and have Infusion site mass?

- Check whether Infusion site mass is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dilaudid:

Dilaudid (96,466 reports)

Browse all side effects of Dilaudid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Infusion site mass:

Infusion site mass (234 drugs)

Browse all the conditions that are associated with Infusion site mass:

Infusion site mass (127 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on hydromorphone hydrochloride (the active ingredients of Dilaudid) and Dilaudid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.